ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY)
November 10, 2025 7:29 AM ESTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY).
The analyst comments "We attended the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 annual meeting where ARS presented the initial results from the neffyExperience program alongside a number of posters on neffy. Based on a... More
